Intensity Therapeutics Q3 net loss $2.7M; pauses two trials, extends cash runway to Q1 2027

INTENSITY THERAPEUTICS, INC.

Net loss $2.7M for Q3 2025 vs $3.5M YoY; cash $7.1M at Sept 30, plus $6.1M raised in Q4 2025.
INVINCIBLE-4 study paused; plans protocol amendment in Q1 2026 to revise INT230-6 dosing, restart enrollment Q1 2026.
INVINCIBLE-3 study paused since March 2025 due to funding constraints; 21 patients enrolled, plan to restart with sufficient funding.
IT-01 study published in eBioMedicine: 75% disease control rate, 11.9 mo median OS; 20% abscopal effects in >40% tumor burden group.
Capital raises: $7.5M ATM in Q3, $2.1M ATM in Oct, $4.0M registered direct offering in Oct; cash runway extended to Q1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.